© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Lebrikizumab Improves Patient-Reported Outcomes in Atopic Dermatitis for Patients Previously Treated with Dupilumab
March 08, 2025
The proportion of participants with poor response to dupilumab who achieved a PNRS improvement of 3 points or greater was 72.9% at week 16 and 77.5% at week 24.
Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis
March 07, 2025
By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.
Roflumilast Foam 0.3% Significantly Reduces Pruritus and Improves Quality of Life in Scalp and Body Psoriasis
March 07, 2025
More than half (55.4%) of roflumilast-treated patients achieved a score of 0 or 1 vs 19.8% in the vehicle group on the Worst Itch-NRS numeric rating scale.
Roflumilast Cream 0.15% Well Tolerated in Atopic Dermatitis Patients with Prior Treatment Failures
March 07, 2025
Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.
AAD 2025 preview: Dermatologist Mona Shahriari, MD, on Roflumilast and Other Nonsteroidal Topicals for Atopic Dermatitis
March 07, 2025
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer as physicians prepare for AAD 2025.
First Rivaroxaban Generics (2.5 mg) Get FDA Approval
March 05, 2025
The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.
Colonoscopy Bowel Prep Guidelines Updated by US Multi-Society Task Force on Colorectal Cancer
March 05, 2025
New evidence-based guidance for bowel prep considers patient preference and history and updates timing of prep regimen, dietary restrictions, and follow-up recommendations.
Investigational Ketogenic Diet Pill BL-001 Shows Significant Weight Loss in Phase 1 Trial
March 05, 2025
Overweight individuals in the highest dose group with weight loss at day 28 continued to lose weight at the 2-week follow-up, with metabolic changes mimicking ketogenic effects.
Obesity Will Affect One-Half of Adults, One-Third of Youth Worldwide by 2050
March 04, 2025
Posing an unparalleled threat of premature disease and death globally, the unchecked rise in overweight and obesity requires an urgent 5-year action plan, experts say.
FDA Pre-NDA Meeting for AXS-05 in Alzheimer's Disease Sets Stage for sNDA Submission in Q3 2025
March 04, 2025
Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.